GlassScriptPhysician profile
Quentin A Mewborn
NPI 1831240308
$15,100.28
in general payments reported to CMS, 2019-2025
61 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,763 · 2021: $3,014 · 2022: $2,379 · 2023: $2,488 · 2024: $1,658 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,290 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,290.09 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,257.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,809.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,795.45 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $847.65 | 2019-2025 | |
| Abbvie INC. | $787.07 | 2019-2025 | |
| Lilly USA, LLC | $667.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $651.51 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $515.55 | 2021-2025 | |
| Amarin Pharma, INC. | $453.69 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.94 | 2021-2025 | Jardiance |
| Abbott Laboratories | $329.52 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Kowa Pharmaceuticals America, INC. | $318.06 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Axsome Therapeutics, INC. | $316.90 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $307.95 | 2019-2022 | |
| Esperion Therapeutics, INC. | $280.73 | 2020-2025 | Nexletol |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quentin Mewborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.